Abstract

Human parvovirus B19 (B19V) traffics to the cell nucleus where it delivers the genome for replication. The intracellular compartment where uncoating takes place, the required capsid structural rearrangements and the cellular factors involved remain unknown. We explored conditions that trigger uncoating in vitro and found that prolonged exposure of capsids to chelating agents or to buffers with chelating properties induced a structural rearrangement at 4 °C resulting in capsids with lower density. These lighter particles remained intact but were unstable and short exposure to 37 °C or to a freeze-thaw cycle was sufficient to trigger DNA externalization without capsid disassembly. The rearrangement was not observed in the absence of chelating activity or in the presence of MgCl2 or CaCl2, suggesting that depletion of capsid-associated divalent cations facilitates uncoating. The presence of assembled capsids with externalized DNA was also detected during B19V entry in UT7/Epo cells. Following endosomal escape and prior to nuclear entry, a significant proportion of the incoming capsids rearranged and externalized the viral genome without capsid disassembly. The incoming capsids with accessible genomes accumulated in the nuclear fraction, a process that was prevented when endosomal escape or dynein function was disrupted. In their uncoated conformation, capsids immunoprecipitated from cytoplasmic or from nuclear fractions supported in vitro complementary-strand synthesis at 37 °C. This study reveals an uncoating strategy of B19V based on a limited capsid rearrangement prior to nuclear entry, a process that can be mimicked in vitro by depletion of divalent cations.

Highlights

  • Human parvovirus B19 (B19V) commonly causes a mild childhood disease known as erythema infectiosum, or fifth disease [1]

  • After 30 min, a similar signal with. These results are in line with our previous studies where we have shown that Bafilomycin A1 (BafA1) inhibits a characteristic endocytic distribution was observed in untreated or BafA1-treated cells

  • These results are in line with our previous studies where we have shown that BafA1 inhibits B19V

Read more

Summary

Introduction

Human parvovirus B19 (B19V) commonly causes a mild childhood disease known as erythema infectiosum, or fifth disease [1]. The virus can cause a range of clinical manifestations, and infection during pregnancy may result in hydrops fetalis and foetal death [2]. Viral capsids assemble as highly stable structures to retain and protect the genome during their extracellular phase. They have a built-in ability for disassembly when entering a new host cell. These apparently contradictory functions are possible because the robust protective capsids are metastable. They are conceived to rearrange upon specific cellular cues, adopting a sequence of structural configurations in a stepwise manner. Those configurations enable the intracellular transport of capsids and the release of the genome in the appropriate cell compartment for replication [4]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.